Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.

× No keyword cloud information.

8 in total

Review 1. Complications of long-term therapy for ANCA-associated systemic vasculitis.

Authors: Nadezhda Wall; Lorraine Harper
Journal: Nat Rev Nephrol Date: 2012-06-05 Impact factor: 28.314

Review 2. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases.

Authors: Despoina Papadopoulou; Nikolaos V Sipsas
Journal: Rheumatol Int Date: 2013-12-10 Impact factor: 2.631

3. Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs.

Authors: Manjeet Bhati; Syamasis Bandyopadhyay
Journal: Clin Rheumatol Date: 2016-06-22 Impact factor: 2.980

4. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.

Authors: Dae Hyun Yoo; Chang-Hee Suh; Seung Cheol Shim; Slawomir Jeka; Francisco Fidencio Cons Molina; Pawel Hrycaj; Piotr Wiland; Eun Young Lee; Francisco G Medina-Rodriguez; Pavel Shesternya; Sebastiao Radominski; Marina Stanislav; Volodymyr Kovalenko; Dong Hyuk Sheen; Leysan Myasoutova; Mie Jin Lim; Jung-Yoon Choe; Sang Joon Lee; Sung Young Lee; Sung Hwan Kim; Won Park
Journal: BioDrugs Date: 2017-08 Impact factor: 5.807

BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.

Review 1. Complications of long-term therapy for ANCA-associated systemic vasculitis.

Review 2. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases.

3. Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs.

4. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.

5. Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic.

Review 6. Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.

7. Immunoglobulin abnormalities are frequent in patients with lupus nephritis.

8. Listeria meningitis and resultant symptomatic hydrocephalus complicating infliximab treatment for ulcerative colitis.